Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Every day we have great news
This stock will be trading in dollars not cents, I’ Sure
Today will reach 25 cents at least
Woooooow, what a great news
Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem® Female Infertility/Ovarian Failure Treatment
2/10/21, 7:45 AM
PHOENIX, Feb. 10, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female infertility/ovarian failure treatment. OvaStem®, which is covered by issued patent #10,792,310, involves injection of stem cells into dysfunctional ovaries and has been demonstrated to induce fertility, as well as restore hormone levels.
Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)
The data, which are covered in a newly filed patent application, demonstrate that mesenchymal stem cell injection results in generation of T regulatory cells. These cells are a type of immune cell which the Company has previously patented for regeneration of lumbar discs (US Patent #10,842,815). Importantly, depletion of T regulatory cells resulted in negation of the beneficial effects of stem cells, whereas exogenous administration of T regulatory cells are capable of restoring ovarian function.
"Cellular therapy is making significant advances in the treatment of cancer, degenerative diseases, and autoimmunity." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "We are pleased to discover this interesting interaction between mesenchymal stem cells and T regulatory cells in prevention of ovarian failure and restoration of function. By elucidating mechanisms, we feel we are making progress towards eventual filing with the FDA for initiation of clinical trials."
Although the menopause market is believed to be approximately $600 billion[1], the Company is focusing on the initial indication of premature ovarian failure. Premature ovarian failure occurs in woman under 40 who experience degeneration of ovaries from a variety of conditions. The Company has demonstrated efficacy of autologous (patient's own stem cells) and allogeneic (universal donor) in animal models of this condition.
"Despite having a wide variety of cellular products in development, there appears to be a common theme of interaction between mesenchymal stem cells and T regulatory cells." Said Timothy Warbington, President and CEO of the Company. "Today's discovery that T regulatory cells are effective in treatment of ovarian failure lends more scientific support to OvaStem®, which we hope will accelerate our path towards FDA clinical trials to treat this condition."
What a great 8K released after hours, tomorrow Celz will reach 10 cents easily
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 1, 2021
Creative Medical Technology Holdings, Inc.
(Exact name of registrant as specified in its charter)
Nevada
000-53500
87-0622284
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification Number)
211 E Osborn Road, Phoenix, AZ 85012
(Address of principal executive offices)
(833) 336-7636
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
N/A
N/A
N/A
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 8.01. Other Events
On February 1, 2021, Creative Medical Technology Holdings, Inc. (the “Company”), issued a press release with respect to data demonstrating that administration of the Company’s ImmCelz® regenerative immunotherapy to animals resulted in a significant surge of the protein hepatocyte growth factor (HGF-1).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1
Press release issued by the Company dated February 1, 2021
2
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Creative Medical Technology Holdings, Inc.
Date: February 8, 2021
By:
/s/ Timothy Warbington
Timothy Warbington, Chief Executive Officer
3
EXHIBIT 99.1
Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity
Company Demonstrates that in Addition to Activating Endogenous Stem Cells and T Regulatory Cells
ImmCelz® Induces Surge of Therapeutic Protein HGF-1
February 1, 2021 - Phoenix, AZ (OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a variety of conditions results is a significant surge of the protein hepatocyte growth factor (HGF-1). When scientists blocked the effects of HGF in ImmCelz® treated animals, the therapeutic effects were significantly inhibited. The data suggests one of the molecular mechanisms of action of ImmCelz® is mediated by production of this therapeutic molecule.
“One of the drawbacks of many cellular therapies is their complicated, and many times ill-defined mechanisms of action.” Said Dr. Amit Patel, co-founder of the company and co-inventor of the patent application. “I am proud of our scientific team for focusing not only on the exploration of therapeutic benefits of ImmCelz® in a wide variety of diseases, but also on homing in on mechanisms of action. We have previously reported ImmCelz® induces T regulatory cells and endogenous neurogenesis1. The current data suggest that HGF-1 may be acting upstream of these effects.”
To date the Company has reported therapeutic activity of ImmCelz® in models of rheumatoid arthritis2, stroke3, type 1 diabetes4, kidney failure5 and liver failure6. The data disclosed today are supported by independent studies which have shown HGF-1 is capable of inducing T regulatory cells7,8 and stimulating neurogenesis9,10.
“Cellular immunotherapy has commanded extremely lucrative valuations for companies in early stages of clinical trials.” Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “We believe for regenerative immunotherapy products such as ImmCelz® to attract similar valuations, understanding of biological mechanisms of action is important. I commend our scientific collaborators for their work that resulted in this current patent filing.”
______________________
1 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
2 Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model | BioSpace
3 Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity (prnewswire.com)
4 Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes (prnewswire.com)
5 Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy (prnewswire.com)
6 Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model | Nasdaq
7 https://pubmed.ncbi.nlm.nih.gov/22158517/
8 https://pubmed.ncbi.nlm.nih.gov/20332205/
9 https://pubmed.ncbi.nlm.nih.gov/21683144/
10 https://pubmed.ncbi.nlm.nih.gov/20963849/
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and is listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Timothy Warbington, CEO
CEO@CreativeMedicalHealth.com
Creativemedicaltechnology.com
www.StemSpine.com
www.Caverstem.com
www.Femcelz.com
ImmCelz.com
Wooow huge news
PHOENIX, Feb. 8, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British Columbia to the Company's Scientific Advisory Board.
Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)
Dr. Du is a top researcher in the area of molecular and immunological understanding of kidney failure and transplant rejection. Dr. Du is funded by numerous national and international organizations including the Kidney Foundation and the Canadian Institutes of Health Research.
"I am honored to work with Creative Medical Technology Holdings in this fascinating field of leveraging reprogrammed immune cells for regenerating injured kidneys." Said Dr. Du. "To date people think about regenerative medicine and immunology as separate fields. It is very exciting to consider the possibility that immune cells can act as a catalyst for regenerative processes: this is the basis of the ImmCelz® product."
ImmCelz® is a personalized cell therapy generated by incubation of patient cells with allogeneic JadiCell stem cells under proprietary conditions. The JadiCell possess potent ability to reprogram the immune system, as exemplified in part by their ability to significantly extend survival of COVID patients in an FDA double blind, placebo controlled, clinical trial1. ImmCelz® has been demonstrated effective in animal models of rheumatoid arthritis2, liver failure3, stroke4, type 1 diabetes5 and kidney failure6. Scientific studies suggest ImmCelz® functions through secretion of a fundamentally important molecule called Hepatocyte Growth Factor7, as well as stimulation of T regulatory cells, a type of immune system cell that suppresses pathological immunity8.
"As a clinical-stage biotechnology company, having already commercialized other stem cell products, we understand the key to any success is based on the ability to attract scientific key opinion leaders." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Dr. Du is a visionary and pioneer in understanding of kidney diseases and we wholeheartedly look forward to him joining our scientific advisory board."
The Advisory Board of Creative Medical Technology Holdings includes internationally renowned neurologist Santosh Kesari MD, Ph.D, the former head of cardiology at Cedar Sinai Medical Center Timothy Henry, MD and our Director Dr. Amit Patel, inventor of the JadiCell and the first physician to have implanted stem cells into the human heart.
Look guys, I’ sure that Rnva will be trading in dollars not cents in the coming weeks.
Maybe you say that I’m dreaming, but there is a lot of examples in OTC market.
Take a look to TSNP, from 0.0001 on Oct.22, 2020 to 1.69 yesterday.
GLTA
Look guys, I think something is cooking, and Hmny will be trading in dollars not cents in the coming weeks.
Maybe you say that I’m dreaming, but there is a lot of examples in OTC market.
Take a look to TSNP, from 0.0001 on Oct.22, 2020 to 1.69 yesterday.
GLTA
Look guys, Celz has a great products and bright future, I’m sure it will be trading in dollars not cents in the coming weeks.
Maybe you say that I’m dreaming, but there is a lot of examples in OTC market.
Take a look to TSNP, from 0.0001 on Oct.22, 2020 to 1.69 yesterday.
GLTA
It’s so clear, calm before a huge storm
You will see Celz up more than 500% at any moment
Celz will reach 0.213 level that tested by Market Makers last month
Market Makers clearly accumulating at this level in preparing to the next jump
Wooow, what a great news, Celz will be trading in dollars in the next weeks, I’m sure
PHOENIX, Feb. 1, 2021 /PRNewswire/ -- (OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a variety of conditions results is a significant surge of the protein hepatocyte growth factor (HGF-1). When scientists blocked the effects of HGF in ImmCelz® treated animals, the therapeutic effects where significantly inhibited. The data suggests one of the molecular mechanisms of action of ImmCelz® is mediated by production of this therapeutic molecule.
"One of the drawbacks of many cellular therapies is their complicated, and many times ill-defined mechanisms of action." Said Dr. Amit Patel, co-founder of the company and co-inventor of the patent application. "I am proud of our scientific team for focusing not only on the exploration of therapeutic benefits of ImmCelz® in a wide variety of diseases, but also on homing in on mechanisms of action. We have previously reported ImmCelz® induces T regulatory cells and endogenous neurogenesis.1 The current data suggests that HGF-1 may be acting upstream of these effects."
To date the Company has reported therapeutic activity of ImmCelz® in models of rheumatoid arthritis,2 stroke,3 type 1 diabetes,4 kidney failure5 and liver failure.6 The data disclosed today are supported by independent studies which have shown HGF-1 is capable of inducing T regulatory cells7,8 and stimulating neurogenesis.9,10
"Cellular immunotherapy has commanded extremely lucrative valuations for companies in early stages of clinical trials." Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "We believe for regenerative immunotherapy products such as ImmCelz® to attract similar valuations, understanding of biological mechanisms of action is important. I commend our scientific collaborators for their work that resulted in this current patent filing."
Celz was discussed on Reddit 3 days ago
Prepare yourself for a huge week like Gme & Amc
“Guys Check out this little gem CELZ . Only If you have time:)
Stroke IND application should be getting a response from FDA . They also should be submitting IND applications for heart, liver, and kidney studies too. The latest patent could greatly reduce the need for dialysis, and there are more patents and more IND applications . If the IND studies on stroke (and the upcoming IND applications for heart, liver, kidney, etc.) get approval to proceed and they go well, this suddenly could be a multi-billion dollar enterprise. And most likely a potential Buy out target . Today's closing price is around 0.0250 :) it is kind of a joke. Outstanding Shares 750,957,283 / Float under 500M and Insider ownership around 33.44% . There is a small Friendly community at Stocktwits and also at Yahoo. Since CELZ don't have much exposure. My intention is to help our community to get the story out. MM manipulation is happening bcoz only few people know about CELZ. If everything works out CELZ would potentially provide permanent cures! Not just treating Symptoms. I believe they already have a product. That one is having success for ED and they also seems to be working towards finding effective treatment for Covid . Hopefully with time more and more people will do DD. My only request to CELZ management is when they get Profitable ( Which I think they are already or close to) or when they receive funding via Partnership. They should consider to use part of the capital for share Buy back and think about Up-listing to Nasdaq. And finally guys I'm not any financial adviser or anything like that. Kindly do your own DD.”
Thank you!
February will be a promising month for Celz
Prepare yourself for FDA approval or buyout
Celz will be trading in dollars not cents in the coming weeks
Patient Celzers will be millionaires this year
Mark my post
If Celz up 1000% or more, it’s logically to see that cuz it’s a company with a great products and bright future not like Gamestop which up from $2 to $513 in just one month
Once Celz cross 0.0485 level, no resistance until 0.213, and once reach this level, next resistance is 1.0795
Chart talks
Celz will reach 0.213 first on the road of dollar area , that price we saw 2 weeks ago and all said it’s a mistake, no it’s real guys.
Maybe you will see this price next week.
Remember Celz was up 670% in just one day last month.
Only patient Celzers will be millionaires, I’m sure.
Market makers just shake the tree in the last 2 weeks to make weak hands sold, and they will start the journey to dollars land.
GLTA
Look guys
Celz will reach 0.213 first on the road of dollar area , that price we saw 2 weeks ago and all said it’s a mistake, no it’s real guys.
Maybe you will see this price tomorrow or Friday.
Remember Celz was up 670% in just one day last month.
Only patient Celzers will be millionaires, I’m sure.
Market makers just shake the tree in the last 2 weeks to make weak hands sold, and they will start the journey tomorrow to dollars land.
GLTA
Chart talks bro.
Be careful shorts, with or without news, once we cross 0.0290 level, no resistance after that
What a great news, I’m sure this stock will be trade in dollars not cents in the coming weeks not months
PHOENIX, Jan. 27, 2021 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney failure in an animal model. Using the classical "ischemia/reperfusion" system, collaborators of the Company demonstrated significant reduction in markers of kidney injury at multiple timepoints after kidneys were clamped to replicate renal injury
"Kidney failure is a significant cause of suffering today. One particular area of kidney damage that is of great interest is preventing injury associated with cardiovascular bypass. One report states that as many as 30% of patients undergoing bypass have some level of renal damage1." Said Dr. Amit Patel, co-inventor of the patent and Board Member of the Company. "The preliminary animal data suggests that ImmCelz® may have superior activity to conventional stem cell based approaches. This may be due to the smaller size of immune cells that comprise the ImmCelz® product, as well as due to factors we are still investigating."
According to a BCC Research Report, entitled "Chronic Kidney Disease: Global Markets and Technologies Through 2023" the global market for chronic kidney disease is anticipated to grow from $79.0 billion in 2018 to reach $95.0 billion by 2023 at a compound annual growth rate (CAGR) of 3.8% for the period of 2018-20232.
"It is important to note that the JadiCell, which has been demonstrated by a double-blind placebo controlled clinical trial to be effective against COVID-19 lung failure3, is the "engine" behind ImmCelz® said Timothy Warbington, President and CEO of the Company. "The demonstration that this cell type, which already has cleared FDA trials, can bestow regenerative properties to blood cells is, in our minds, paradigm shifting. We are excited to include this technology in our robust intellectual property portfolio and eager to file our Investigational New Drug application (IND) with the FDA to begin clinical trials."
The JadiCell clinical trial consisted of 24 patients randomized 1:1 to either JadiCell (UC-MSC) treatment (n = 12) or the control group (n = 12). According to the publication, treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS4.
Wow, great news
Every day new news
Celz to the moon
PHOENIX, Jan. 21, 2021 /PRNewswire/ -- (OTC – CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Boris Reznik to the Company's Scientific Advisory
Dr. Reznik is a veteran of multiple startups and has a strong track record of building companies across a diverse set of technologies-based industries with biomedical sciences being one of his primary focuses.
His company, Biorasi, global CRO ran an excess of 500 clinical trials and obtained numerous FDA approvals. Dr. Reznik led Biorasi to being awarded the INC 500 "Fastest Growing Company" Award and to a successful exit.
Boris Reznik is the Chairman of Venvalo Group, venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems – a unique perspective in the drug and device development world.
"I am proud to be one of the early investors in Creative Medical Technology Holdings. Its executives are one of the most driven, motivated and talented teams that I have had the pleasure of investing in. I am honored to be invited as a partner to accelerate development of ImmCelz® to help patients with heart failure, liver failure, diabetes, and stroke, as well as aiding in their ongoing development of other assets in their robust portfolio" Said Dr. Reznik.
"Working with Dr. Reznik will allow us to "fast forward" the development process of ImmCelz®, as well as other cellular therapies currently in development." Said Dr. Amit Patel, Board Member of the Company and co-founder. "I have previously collaborated with Dr. Reznik on numerous projects and I am excited to witness the unfolding of Dr. Reznik's life mantra of "Creating Value from Potential™"
"Dr. Reznik's involvement in our clinical development plan, as well as his overall corporate and strategic insight will synergize with our existing strengths to significantly enhance shareholder value." Said Timothy Warbington, President and CEO of the Company. "I enjoy working with Dr. Reznik because of his unique multidisciplinary, multidimensional, "systems based" approach to handling complicated problems. We look forward to bringing life-saving therapies to fruition as quickly as possible."
This week is your week Celzers
The price of 21 cents you saw last week wasn’t fake, you will see it clearly this week
What a huge news
PHOENIX, Jan. 19, 2021 /PRNewswire/ -- (OTC: CELZ) Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes
In a series of experiments using the non-obese diabetic model, administration of ImmCelz® was able to reduce incidence of diabetes, but also to reverse diabetes in several mice. Molecular analysis revealed that ImmCelz® administration was associated with increase production of regenerative cytokines such as VEGF, EGF, IGF, and HGF, all of which have been implicated in regeneration of damaged pancreatic tissues.
"More than 10 years ago, together with my collaborators, we have demonstrated ability to modulate destruction of, and even regenerate, pancreatic tissue by utilization of various cellular therapies1," said Thomas Ichim, Ph.D, and co-inventor of the patent. "To be able to induce production of the pancreas from autoimmunity by utilization of immune based regenerative technologies is, to my knowledge, a completely new and promising area of addressing the issue of type 1 diabetes."
While numerous approaches have been utilized to reduce immunogenicity of pancreatic tissue, the ImmCelz® approach appears superior because of the possibility of inducing a form of "regenerative memory" in which T cell are endowed with ability to repair damaged tissues.
"The data disclosed today support the possibility that ImmCelz® truly is a form of 'regenerative immunotherapy,' " said Dr. Amit Patel, co-inventor of the patent. "To my knowledge this is the first cellular therapy in which immune cells, particularly T cells, are programmed by coculture with umbilical cord stem cells to generate a product that actually induces production of regenerative cytokines in vivo."
"The ongoing influx of positive experimental data supports the notion that ImmCelz® is a promising therapeutic platform that has ability to address many unmet medical needs associated with degeneration and inflammation," said Timothy Warbington, President and CEO of the Company. "Our vision is that one day ImmCelz® will be for degenerative diseases what CAR-T cells were for hematology."
It’s so clear that 0.0115 level tested last week was the bottom
This week will be huge
Prepare yourself to see Rnva up 10x this week
Remember that Rnva was 0.25 less than 3 months ago on Oct.25, 2020
Celz will see 21 cents this week
Market makers tested this level last week
Look guys, with news or without news, depending on chart info, when 50 days moving average cross 200 days from the bottom, means Celz will skyrocketing this week
There are many investors buy depending on chart not news
This week will be huge
Today is our day Celzers
What a huge news
Today will skyrocketing to 10 cents
https://regenerativeacademy.com/thomas-ichim/
In the past Thomas E. Ichim was Director & Chief Scientific Officer at Regen Biopharma, Inc., Vice President-Cellular Therapies at Intrexon Corp. and President, Director & Chief Scientific Officer at Medistem, Inc. (a subsidiary of Intrexon Corp.) and Program Manager at Biorasi LLC (he founded the company in 2004)
Just noticed that he was Director & Chief Scientific Officer at Medistem, Inc.
I think there’s a buyout for Celz in the near future
Celz was under focus during weekend, many are decided to buy
Be careful Celzers
Don’t let market makers steel your shares at this low level, they know Celz will be in $ in the coming weeks
0.0340 premarket up 22.30%
Celz will skyrocketing today
Actually I see buyout from a big pharmaceutical company
With all these huge news, many companies will be in a race to buy Celz
"As we round out 2020, we have significantly expanded our Intellectual Property portfolio based on many years of collaborative research and development. Utilizing the ImmCelz® technology for the treatment of heart failure is an excellent addition to this robust patent portfolio as it effects millions of patients in the U.S. alone. Patients with end stage heart failure in many cases have no options but heart transplantation, which is extremely limited." Said Timothy Warbington, President and CEO of the Company. "We are excited with the progress that the Company is making in advancing ImmCelz®, which approaches regenerative medicine from a completely unique perspective. Given that the active cells in ImmCelz® are derived from the same patient, we anticipate an accelerated path to FDA Investigational New Drug (IND) clearance."
"We encourage industry colleagues and other interested parties to review our early priority date patent filings to learn more about the ImmCelz® technology and how it applies to multiple indications" Mr. Warbington further said
What a huge news
This stock should be trading in dollars next week
I ‘m sure, just be patient
Look to TPTW up 50% today, not like your garbage RNVA
Up from 0.0007 to 0.07, just up 10,000% in just 3 months, not like this shitty company
Woooooow
What a strong day are you talking about man?
Down 28%, and during the day down 60%
Sorry to say that your shares need another two days to be adjusted in your account, but at that time, Rnva will be trading at 0.10 or below
First day down 28%
Imagine tomorrow when pre Rs investors which their shares locked today starting to sell their shares!!
Tomorrow will down huge
I think it will return back to 0.0001 in just a month or two